Background. Hepatic injury induced by ischemia-reperfusion (I/R) after transplantation or lobectomy is a major clinical problem. The potential benefit of remifentanil in these hepatic surgeries remains unknown. The current study investigated whether remifentanil protects the liver against I/R injury in a rat model and whether the underlying mechanism involves the modulation of interleukin (IL)-18 signaling. Methods. Male Sprague-Dawley rats were subjected to 45 minutes of partial hepatic ischemia followed by 6 hours of reperfusion. Then, they received an intravenous saline or remifentanil (0.4, 2, or 10 μg/kg per minute) infusion from 30 minutes before ischemia until the end of ischemia with or without previous administration of naloxone, a nonselective opioid receptor antagonist. Serum aminotransferase, hepatic morphology, and hepatic neutrophil infiltration were analyzed. The expression of hepatic IL-18; IL-18-binding protein (BP); and key cytokines downstream of IL-18 signaling were measured. Results. Remifentanil significantly decreased serum aminotransferase levels and profoundly attenuated the liver histologic damages. Liver I/R injury increased the expression of both hepatic IL-18 and IL-18BP. Although remifentanil pretreatment significantly decreased I/R-induced IL-18 expression, it further upregulated IL-18BP levels in liver tissues. The I/R-induced increases of hepatic interferon-γ, tumor necrosis factor-α and IL-1β expression, and neutrophil infiltration were also significantly reduced by remifentanil. Naloxone inhibited the remifentanil-induced downregulation of IL-18, but not the elevation of IL-18BP, and significantly attenuated its protective effects on liver I/R injury. Conclusions. Remifentanil protects the liver against I/R injury. Modulating the hepatic IL-18/IL-18BP balance and inhibiting IL-18 signaling mediate, at least in part, the hepatoprotective effects of remifentanil.
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A s one of the most common complications associated with liver transplantation, lobectomy, massive trauma or hemorrhagic shock, liver ischemia/reperfusion (I/R) injury is the main cause of liver failure.
1,2 The prolonged ischemic insult followed by the restoration of hepatic blood flow initiates a complex injury that is characterized by exaggerated inflammation and microvascular dysfunction. 3, 4 Currently, effective therapy for liver I/R injury is quite lacking, and exploring potential therapeutic and preventative strategies for this injury has been an active topic in recent years.
Interleukin (IL)-18 is an 18-kDa cytokine that is synthesized by Kupffer cells and activated macrophages. 5 It was originally named interferon (IFN)-γ-inducing factor because it contributes to the differentiation and proliferation of IFN-γ from T cells and natural killer cells and plays a key role in Th1 immune responses. 6 In addition, it activates the DNAbinding activity of transcription factors nuclear factor (NF)-κB and activator protein-1, therefore initiating a cascade of inflammatory cytokines, such as tumor necrosis factor (TNF)-α and IL-1β. 7, 8 It also mediates neutrophil recruitment in numerous tissues, including the kidney, brain, and liver. [9] [10] [11] Interleukin-18 has a natural inhibitor, IL-18-binding protein (BP), which binds IL-18 with high affinity and blocks its activity. 5 In the past years, multiple studies have reported that IL-18 plays a prominent role in the pathophysiology of liver I/R injury. In a mouse hepatic I/R model, a significant upregulation of IL-18 levels in the liver was demonstrated. 9 Both neutralization of IL-18 with its antibody and the downregulation of IL-18 by silencing its upstream mediator, nodelike receptor family pyrin domain-containing 3, result in remission of liver I/R injury. 9, 12 Hence, IL-18 is now considered an essential factor in inflammation-associated I/R injury, and targeting IL-18 signaling pathways may provide therapeutic benefit for this type of injury. remain unknown. Previous studies have reported that remifentanil and other opioids can modulate the activities of several transcription factors, including NF-κB, signal transducer and activator of transcription 1 and CCAAT/ enhancer-binding protein β. [15] [16] [17] Because the activation of NF-κB can induce IL-18 expression 18 and because signal transducer and activator of transcription 1 and C/enhancerbinding protein β are essential transcription factors for the regulation of IL-18BP gene expression, 19, 20 in combination with the key point that IL-18 signaling plays an important role in liver injury, it is reasonable to hypothesize that remifentanil could modulate IL-18 signaling through its impact on IL-18 and/or IL-18BP expression and thus ameliorate liver I/R injury. The current study was undertaken to test this hypothesis in a clinically relevant rat model. Our findings provide valuable information for the clinical application of this anesthetic during perioperative periods.
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats (Shanghai SLAC Laboratory Animal Co. Ltd, Shanghai, China) weighing 250 ± 20 g were used in all experiments. The animal project was approved by the Animal Care and Use Committee of Shanghai Jiaotong University, Shanghai, China. Animals were fed rat chow with free access to water and housed in a temperature and humidity-controlled room with a 12-hour light/dark cycle.
Experimental Protocol
Partial hepatic I/R injury model was performed as described previously. 21 Briefly, rats were anesthetized with pentobarbital sodium (50 mg/kg, intraperitoneally). After tracheal intubation, mechanical ventilation was provided with a rodent respirator (Kent Scientific Corporation, Torrington, CT) with 50% O 2 and 50% room air at 60 to 70 breaths/min. The left femoral vein was cannulated to infuse remifentanil or 0.9% saline. The injury was induced through a median abdominal incision. An atraumatic clip was used to interrupt the vascular supply to the left and median lobes of the liver. After maintaining ischemia for 45 minutes, the clamp was removed, and the liver was reperfused for 6 hours. Rats were sacrificed by exsanguination from the inferior vena cava after anesthesia at the end of experiment, and the ischemic lobes and blood samples were collected for future analysis. Throughout the whole process, the rectal temperature was controlled at 35 to 36°C with a heating pad.
The animals were randomly divided into 5 groups (7 rats/ group): (1) the Sham group, (2) the I/R group, and (3-5) the remifentanil-preconditioned I/R groups. Rats in the remifentanil-preconditioned I/R groups received 0.4, 2, or 10 μg/kg per minute of remifentanil (referred to as the R1, R2, and R3 groups, respectively) via an infusion starting 30 minutes before ischemia until the end of ischemia. Remifentanil was diluted in normal saline to equal volume in all groups. Rats in the I/R group proceeded in the same way but received the same volume of 0.9% saline infusion as that of the remifentanil-preconditioned groups. Shamoperated rats underwent the same laparotomy but without vascular occlusion. Additionally, 0.9% saline was injected continuously through the left femoral vein for 75 minutes. All samples were collected 6 hours later.
To investigate whether ORs are involved in the effects of remifentanil, the nonselective OR antagonist naloxone was used. Another set of rats was randomly assigned to one of the following 4 groups (5 rats/group): the I/R group; the remifentanil + I/R group (referred to as the R + I/R group), in which remifentanil was infused intravenously at 0.4 μg/ kg/minutes from 30 minutes before ischemia until the end of ischemia; the naloxone + remifentanil + I/R group (referred to as the Na + R + I/R group), in which rats received an intravenous injection of 1 mg/kg naloxone (Sigma-Aldrich, St. Louis, MO) 5 minutes before remifentanil infusion and then another 1 mg/kg naloxone right before the start of ischemia; and the Naloxone + I/R group (referred to as Na + I/R group), in which rats underwent the same way as Na + R + I/R group but received 0.9% saline infusion instead of remifentanil.
Serum Aminotransferase Measurement
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured with a commercially available kit (Wako Pure Chemical Industries Ltd., Tokyo, Japan) using a Model 7180 autobiochemistry analyzer (Hitachi, Tokyo, Japan).
Histopathological Evaluation and Immunohistochemistry
Liver samples from the ischemic lobes were fixed in 10% formaldehyde, embedded in paraffin, cut into 5-μm sections, and stained with hematoxylin-eosin. The severity of liver I/R injury was evaluated blindly by a pathologist.
For IL-18 and IL-18BP staining, paraffin-embedded slides were incubated with antibodies against IL-18 (sc-7954, 1:50, Santa Cruz Biotechnology Inc., Dallas, TX) and IL-18BP (sc-9464, 1:50, Santa Cruz Biotechnology Inc.) at 4°C overnight followed by horseradish peroxidase-linked antirabbit immunoglobulin (Ig)G (Dako, Carpinteria, CA) and antigoat IgG (Santa Cruz Biotechnology Inc.), respectively. Color was developed with 3,3′-diaminobenzidine (Dako).
Neutrophil infiltration was analyzed by counting the number of neutrophils in 10 randomly selected high power fields (Â40) using liver tissue sections stained with Naphtol AS-D chloroacetate esterase (a neutrophil-specific marker, Naphthol ASD-chloroacetate esterase kit, 91C, Sigma-Aldrich) by a pathologist in a blinded manner. The mean number of neutrophils per field was calculated.
Real-Time Quantitative Polymerase Chain Reaction
Total RNA was extracted from homogenized liver samples using TRIzol method (Invitrogen, Carlsbad, CA), quantitated, and reverse-transcribed to cDNA with PrimeScript RT reagent (Takara, Otsu, Japan) according to the manufacturer's instructions. SYBR green based real-time quantitative polymerase chain reaction (QPCR) was conducted with the following primers: Rat IL-18, 5′-CAACGAATCCCAG ACCAGAC-3′(sense) and 5′-GGGTAGACATCCTTCCAT CCT-3′(antisense); Rat IL-18BP, 5′-GCTCTGGGATGGA TTGAAGAC-3′(sense) and 5′-GGTCAAGGTCATGCTGT GGT-3′(antisense); rat IFN-γ, 5′-TCGAGGTGAACAAC CCACAG-3′(sense) and 5′-CAGAATCAGCACCGACTC CTT-3′(antisense); rat TNF-α,5′-GCTCAGAAACACACG AGACG-3′(sense) and 5′-ATCCACTCAGGCATCGACAT-3′ (antisense); rat IL-1β,5′-TGTCCAGATGAGAGCATCCA-3′
(sense) and 5′-ACGGGCAAGACATAGGTAGC-3′(antisense); rat β actin, 5′-TGTCACCAACTGGGACGATA-3′(sense) and 5′-GGGGTGTTGAAGGTCTCAAA-3′(antisense). Target gene expression of each sample was normalized to its corresponding β actin gene value. Final results were expressed as n-fold change in gene expression relative to the control group, and calculated with the ΔΔCt method as described previously. 22 
Western Blot
Liver samples were homogenized with radio-immunoprecipitation assay lysis buffer (Beyotime, Jiangsu, China) as described previously. 23 Protein concentrations were determined with the bicinchroninic acid protein assay kit (Pierce, Rockford, IL). Equal amounts of protein (50 μg) were separated by 8% to 12% Bis-Tris polyacrylamide gel electrophoresis. Proteins were then transferred onto polyvinylidene difluoride membranes. After blocking with 5% nonfat dry milk in tris buffered saline tween-20, membranes were incubated at 4°C overnight with one of the following primary polyclonal antibodies: anti-IL-18 (AF521, 1:2000; R&D systems Inc., Minneapolis, MN), anti-IL-18BP (sc-9464, 1:200, Santa Cruz Biotechnology Inc.), or anti-glyceraldehyde-3-phosphate dehydrogenase (2118, 1:5000; Cell Signaling Technology, Danvers, MA). The blot was then incubated with horseradish peroxidase-conjugated antigoat (1:4000; Santa Cruz Biotechnology Inc.) or antirabbit (1:5000; Cell Signaling Technology) secondary antibodies. The bands were scanned with Bio-RAD ChemiDoc XRS+ machine with chemiluminescence (Pierce), and quantified by densitometry using Image J software. Results were described as the ratio of target and housekeeping protein expression. FIGURE 1. Remifentanil pretreatment attenuates liver I/R injury. Serum levels of ALT (A) and AST (B) were significantly increased in the I/R group compared with the Sham group. Remifentanil, at doses from 0.4 to 10 μg/kg per minute, significantly reduced ALT and AST levels. No differences were observed among the 3 dosage groups. C, The H&E staining revealed extensive liver injury in the I/R group rats, including areas of necrosis, sinusoidal congestion, and structural derangement. At all 3 doses, remifentanil profoundly ameliorated I/R-induced liver histologic changes. R1, R2, and R3: groups of rats receiving remifentanil infusion of 0.4, 2, and 10 μg/kg per minute, respectively, starting 30 minutes before the I/R procedure until the end of the procedure. n = 7 in each group. The data are expressed as the means ± SD. *P < 0.05 versus the Sham group and
Double Immunofluorescent Staining
To assess the expression of IL-18 and Kupffer cells/ macrophages, paraffin-embedded liver sections were deparaffinized, blocked in 3% albumin from bovine serum in phosphate-buffered saline for 30 minutes, and incubated overnight at 4°C with rabbit antirat IL-18 antibody (sc-7954, 1:100, Santa Cruz Biotechnology Inc.) and mouse anti-rat F4/80 antibody (sc-377009, 1:50, Santa Cruz Biotechnology Inc.). The following day, sections were incubated with goat antirabbit Alexa Fluor 488 IgG (GB25303, 1:400, green immunofluorescence; Goodbio Technology Co, Ltd, Wuhan, China) to visualize IL-18 and Cy3-labeled goat antimouse IgG (GB21301, 1:300, red immunofluorescence; Goodbio Technology Co, Ltd) to visualize macrophages. Fluorescencelabeled sections were then mounted with VECTASHIELD (with 4',6-diamidino-2-phenylindole) mounting medium (Vector Laboratories, Burlingame, CA), coverslipped, and viewed using confocal microscopy (Olympus FluoView confocal microscope).
Myeloperoxidase Assay
The liver tissue myeloperoxidase (MPO) levels were analyzed with a commercially available kit (Bio Vision, Milpitas, CA) according to the manufacturer's instructions. Briefly, frozen liver tissues (50-100 mg) were homogenized in 4 volumes of MPO assay buffer and centrifuged at 13,000 g for 10 minutes to remove insoluble materials. The samples were then incubated with Reaction Mix for 120 minutes at 25°C, followed by a reaction with 5-thio-2-nitrobenzoic acid probe. The MPO activity in the supernatant was measured and calculated using the absorbance at 412 nm. One unit of MPO is defined as the amount of MPO that generates enough taurine chloramine to consume 1.0 μmol of 5-thio-2-nitrobenzoic acid per minute at 25°C.
Statistical Analysis
All data are presented as the means ± SD. Data analysis was performed with the statistical software SPSS 19.0. Multiple groups were compared with 1-way analysis of variance, and the 2-tailed Student t test was used to compare results from the 2 groups. Differences were considered significant when P values were less than 0.05.
RESULTS
Remifentanil Pretreatment Attenuates Liver I/R Injury
Forty-five minutes of rat liver ischemia followed by 6 hours of reperfusion induced approximately 18-and 8-fold increases in the serum levels of ALT and AST, respectively, both of which were significantly inhibited by pretreatment with remifentanil (P < 0.01 for all, Figure 1A and B). Hematoxylin-eosin staining revealed that remifentanil profoundly ameliorated I/R-induced histologic changes in the livers, as evidenced by smaller areas of ballooning degeneration, necrosis, and structural derangement in the livers from remifentanil-pretreated rats ( Figure 1C ). These findings are consistent with previous reports by Yang et al 24 and Zhao et al, 25 indicating that remifentanil pretreatment protects liver against I/R injury. However, we did not observe any dose response of remifentanil because no differences were found in the serum aminotransferase levels or hepatic morphology among the three dosage groups.
Remifentanil Decreases I/R-Induced IL-18 Expression and Up-Regulates IL-18BP Synthesis in the Liver
To study the effects of remifentanil on IL-18 and its binding protein, QPCR analyses were performed. As shown in Figure 2A , I/R injury stimulated an almost 2-fold increase in the hepatic IL-18 messenger RNA (mRNA) level (P < 0.001). Pretreatment of remifentanil at all 3 doses significantly inhibited I/R-induced IL-18 mRNA upregulation (P = 0.022, P = 0.038, and P = 0.010 for R1, R2, and R3, respectively). Notably, a slight but significant increase in hepatic IL-18BP mRNA levels was induced in parallel by I/R injury (P = 0.019, Figure 2B ). The addition of remifentanil further increased the expression of this natural inhibitor of IL-18 compared with I/R alone (P < 0.001, P = 0.004 and P = 0.002 for R1, R2 and R3, respectively, Figure 2B ). Western blot analyses confirmed the QPCR results ( Figure 2C and D) , indicating that remifentanil modulates hepatic IL-18 and IL-18BP expression at both the message and protein levels.
To identify the IL-18-and IL-18BP-expressing cells, immunolocalization assays were performed. Immunohistochemistry analysis of liver samples from the I/R group indicated that IL-18 was mainly expressed by Kupffer cells/ macrophages ( Figure 3A) , which was further confirmed by double immunofluorescent staining ( Figure 3C ). Figure 3B showed that remifentanil induced an extensive expression of IL-18BP in hepatocytes in livers from remifentaniltreated rats.
Remifentanil Inhibits I/R-Induced Liver IFN-g Production
To investigate the functional significance of IL-18 inhibition and IL-18BP upregulation by remifentanil, hepatic IFN-γ levels were then examined as a downstream product of IL-18 signaling. A significant increase in IFN-γ expression levels was detected in livers from the I/R group compared with the Sham group (P < 0.001, Figure 4 ). Treatment with all 3 doses of remifentanil decreased I/R-induced IFN-γ expression by approximately 50% (P = 0.002, P = 0.007, and P = 0.005 for R1, R2, and R3, respectively, Figure 4 ). These results suggest that modulation of the IL-18/IL-18BP balance by remifentanil suppresses IL-18 activity in the liver.
Remifentanil Suppresses I/R-Activated IL-18 Downstream Signaling
Next, we examined several key proinflammatory cytokines downstream of IL-18 signaling. The QPCR analysis revealed that pretreatment with remifentanil significantly decreased the expression of TNF-α and IL-1β in I/R livers (P < 0.01 for all, Figure 5A and B). In addition, overt infiltration of neutrophils was observed in the livers of I/R rats, as measured by both MPO activity and Naphtol AS-D chloroacetate esterase stains, whereas the infiltration was significantly reduced in I/R rats treated with remifentanil ( Figure 5C and D) . However, there was no dose-response relationship between remifentanil and its inhibition of IL-18 signaling.
Naloxone Inhibits the Remifentanil-Induced Downregulation of IL-18 But Not the Upregulation of IL-18BP
To characterize the possible role of ORs in the effects of remifentanil, the OR inhibitor naloxone was injected before remifentanil. Pretreatment with naloxone significantly blocked the remifentanil-induced downregulation of IL-18 ( Figure 6A) . However, the upregulation of IL-18BP by remifentanil was not affected by naloxone ( Figure 6B ). An analysis of the serum ALT and AST levels revealed that the addition of naloxone significantly attenuated the protective effects of remifentanil on I/R-induced liver injury ( Figure 6C  and D) , indicating the importance of ORs in these processes. Interestingly, a potent downregulation of serum aminotransferase levels was still observed in I/R rats that received both naloxone and remifentanil compared with those subjected to I/R injury only, indicating that ORs partly mediate the protective effects of remifentanil.
DISCUSSION
Hepatic injury induced by I/R after transplantation or lobectomy is a major clinical problem. The potential benefit of remifentanil in these hepatic surgeries has generated significant interest in recent years, but a definitive conclusion remains elusive. Whereas Yang et al 24 and Zhao et al 25 demonstrated that pretreatment with remifentanil could attenuate liver I/R injury, Ko et al 26 found that patients undergoing right hepatectomy have significantly greater prothrombin time and total bilirubin on postoperative day 5 when anesthetized with remifentanil compared with desflurane. These equivocal findings indicate that further studies are needed to explore the effects of remifentanil on liver I/R injuries.
The current study investigated the effects of remifentanil on I/R-induced liver injury in rats subjected to 45 minutes of partial liver ischemia and 6 hours of reperfusion. A 6-hour time point of reperfusion was chosen because previous studies have demonstrated that both serum levels of transaminases and IL-18 peak between 4 and 8 hours after reperfusion. 9 We found that an intravenous infusion of remifentanil at doses ranging from 0.4 to 10 μg/kg per minute, starting 30 minutes before ischemia, significantly attenuated I/R-induced liver injury. Remifentanil significantly decreased IL-18 expression and increased the level of its natural inhibitor, IL-18BP, in I/R livers. Hepatic expression of key downstream inflammatory mediators of IL-18, including IFN-γ, TNF-α, and IL-1β, as well as tissue neutrophil infiltration, were also suppressed by remifentanil. The addition of naloxone, an OR inhibitor, abolished the remifentanilinduced downregulation of hepatic IL-18 and significantly attenuated its beneficial effects in I/R livers.
Liver I/R injury is a complex procedure characterized by the activation of inflammatory cells and the release of cytokines. Direct evidence supports a prominent role of IL-18 in liver I/R injury. In patients who develop hepatic failure after hepatectomy, increased circulatory IL-18 levels are detected. 27 Similarly, several laboratories have reported significantly elevated IL-18 levels in the livers from animals subjected to I/R injury. 9, 28, 29 Furthermore, neutralizing IL-18 with anti-IL-18 antibodies profoundly alleviates this liver injury. 9 Another study confirmed that IL-18 is required to facilitate neutrophil-dependent hepatic I/R injury. 30 Our results are consistent with previous studies 9, [27] [28] [29] that found an increased expression of hepatic IL-18 in rats undergoing an I/R insult. In addition, we observed that pretreatment with remifentanil significantly inhibited the expression of IL-18 in I/R livers at both the mRNA and protein levels. Remifentanil also reduced the activity of IL-18, as evidenced by reductions in the hepatic IFN-γ levels, TNF-α, and IL-1β expression levels and neutrophil infiltration. Further, when the downregulation of IL-18 expression by remifentanil was abolished by the addition of naloxone, its protective effects on liver injury were significantly attenuated. Taken together, these data indicate that the effects of remifentanil on IL-18 expression are OR-dependent and that inhibiting hepatic IL-18 signaling mediates, at least in part, the hepatoprotective effects of remifentanil.
Interestingly, naloxone cannot totally suppress the beneficial effects of remifentanil in I/R livers, as a potent inhibition of liver injury was still observed in I/R rats receiving both naloxone and remifentanil, indicating that OR-independent mechanisms are involved in the hepatoprotective effects of remifentanil. In the present study, we found that the expression of IL-18BP was simultaneously upregulated by remifentanil in I/R livers. Interleukin-18BP is a well-known endogenous regulator of IL-18 that effectively inhibits IL-18-induced IFN-γ production. 5 Transgenic overexpression of IL-18BP and exogenous IL-18BP administration significantly suppress IL-18 function and attenuate I/R injury in several organs, such as the heart, kidney, and spinal cord. [31] [32] [33] [34] In liver injury models, the protective effects of IL-18BP have also been demonstrated. For example, FIGURE 5 . Remifentanil suppresses I/R-activated IL-18 downstream signaling. The QPCR analyses showed that hepatic TNF-α (A) and IL-1β (B) mRNA levels were significantly increased in livers from rats subjected to 45 minutes of hepatic ischemia followed by 6 hours of reperfusion. At all 3 doses, remifentanil significantly reduced TNF-α and IL-1β expression. Hepatic neutrophil infiltration was assessed by tissue MPO activity (C) and enzyme histochemical staining with Naphtol AS-D chloroacetate esterase (red spots, as shown by arrow) (D). Remifentanil pretreatment significantly down-regulated I/R-induced hepatic neutrophil infiltration. No differences were observed among the three dosage groups. R1, R2, and R3: groups of rats receiving remifentanil infusion of 0.4, 2, and 10 μg/kg per minute, respectively, starting 30 minutes before the I/R procedure until the end of the procedure. n = 5-7 in each group. The data are expressed as the means ± SD. *P < 0.05 versus the Sham group and # P < 0.05 versus the I/R group. Original magnification in D, 40 Â.
Ono et al 35 reported that the specific suppression of IL-18 through overexpressing IL-18BP significantly prolongs survival in a rat liver allograft model. Thus, regulating the balance of IL-18/IL-18BP is now considered a promising therapeutic strategy for IL-18-associated inflammatory diseases. 36 Therefore, we speculate that the upregulation of hepatic IL-18BP expression by remifentanil also contributes to its inhibition on IL-18 signaling. Specifically, our results indicated that remifentanil-induced elevations of IL-18BP were not affected by naloxone, supporting the contention that IL-18BP might be one of the OR-independent mechanisms through which remifentanil protects I/R livers.
The mechanisms underlying the modulation of remifentanil on hepatic IL-18 and IL-18BP expression remain to be determined. Current data indicate that although remifentanil inhibits IL-18 expression through an OR-dependent mechanism, it increases IL-18BP expression via an OR-independent effect. These findings are not surprising because based on our immunolocalization assays, IL-18 is mainly produced by hepatic Kupffer cells/macrophages, which express ORs, 37 whereas IL-18BP is expressed by hepatocytes, which lack ORs. 38 Although remifentanil and other opioids were long thought to exert their effects via the ORs, recent studies have revealed that they also have activities beyond actions at the classical ORs, such as Toll-like receptor activity. 39, 40 Further investigations into the exact receptors and signaling through which remifentanil modulates hepatic IL-18 and IL-18BP expression are ongoing in our laboratory.
Previously, Yang et al 24 reported that the beneficial effects of remifentanil on liver I/R injury are only observed when the doses of remifentanil are higher than 2 μg/kg per minute, whereas in our study, 0.4 μg/kg per minute of remifentanil also showed significant protective effects. The difference is most likely due to different experimental protocols and the timing of detection. We measured liver injury and inflammatory responses at 6 hours after reperfusion, whereas their measurements were performed 2 hours after reperfusion. It is very possible that the anti-inflammatory effects of remifentanil need longer than 2 hours to reach their peak. Further studies are needed to fully explore the optimum time points of remifentanil required for tissue protection. Nevertheless, the current findings show that clinically relevant (0.4 or 2 μg/kg per minute) or larger (10 μg/kg per minute) doses of remifentanil produce similar protections in moderate liver I/R injuries, indicating that a large dosage of remifentanil, which is most likely associated with unwanted side effects, is not necessary to achieve liver tissue protection. In addition, our findings extend previous reports by demonstrating that inhibiting IL-18 signaling is a plausible explanation for the hepatoprotective effects of remifentanil.
In conclusion, our data suggest that remifentanil can modulate the IL-18/IL-18BP balance by reducing IL-18 and FIGURE 6. Naloxone abolishes the downregulation of hepatic IL-18 expression by remifentanil and attenuates its protective effects in liver I/R injury. A, Western blot analyses revealed that hepatic IL-18 levels were significantly lower in rats pretreated with 0.4 μg/kg per minute remifentanil (R + I/R group) compared with those from the I/R group but were comparable in rats receiving both 0.4 μg/kg per minute remifentanil and 2 mg/kg naloxone (Na + R + I/R group) compared with the I/R group rats. B, The addition of naloxone did not affect the remifentanil-induced upregulation of IL-18BP expression. An analysis of serum levels of ALT (C) and AST (D) showed that both aminotransferases were significantly higher in the Na + R + I/R group compared with the R + I/R group but were still lower than those in the I/R group. There was a significant difference in ALT levels between the I/R and Na + R + I/R groups. n = 5 in each group. The data are expressed as the means ± SD. *P < 0.05 versus the I/R group and # P < 0.05 versus the R + I/R group.
upregulating IL-18BP expression levels in I/R livers. Inhibiting hepatic IL-18 signaling mediates, at least in part, the hepatoprotective effects of remifentanil. These findings indicate that remifentanil has advantages in liver surgeries associated with IL-18 signaling activation, such as liver transplantation or lobectomy, because it provides not only analgesia but also tissue protection.
